中国商报（记者 马嘉）2026年第一季度尚未结束，中国创新药出海的“热浪”已扑面而来。从荣昌生物与艾伯维达成的56亿美元合作，到信达生物与礼来基于全新分子的88.5亿美元潜在交易，再到前沿生物将小核酸管线授权给葛兰素史克（GSK）……2026年开年，中国药企出海节奏密集，截至2月25日，年内中国创新药已发生44起对外授权（license-out）交易事件，首付款约为31.23亿美元，总金额达...
Source Link中国商报（记者 马嘉）2026年第一季度尚未结束，中国创新药出海的“热浪”已扑面而来。从荣昌生物与艾伯维达成的56亿美元合作，到信达生物与礼来基于全新分子的88.5亿美元潜在交易，再到前沿生物将小核酸管线授权给葛兰素史克（GSK）……2026年开年，中国药企出海节奏密集，截至2月25日，年内中国创新药已发生44起对外授权（license-out）交易事件，首付款约为31.23亿美元，总金额达...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.